Merck Annual Report 2000

Raymond V. Gilmartin, age 60
    June 1994 - chairman of the Board (since November, 1994), president and chief executive officer

David W. Anstice, age 52
    January 1997 - president, The Americas and U.S. Human Health: responsible for the Company's human health business in the United States, Canada and Latin America
    September 1994 - president, Human Health-U.S./Canada: responsible for the Company's prescription drug business in the United States and Canada and worldwide human health marketing

Paul R. Bell, age 55
    April 1997 - president, Human Health-Asia Pacific: responsible for the Company's prescription drug business in the Far East, Australia, New Zealand and Japan
    March 1994 - vice president, Merck Sharp & Dohme Australia and New Zealand

Richard T. Clark, age 55
    January 2000 - president, Merck-Medco Managed Care, L.L.C., a wholly-owned subsidiary of the Company
    June 1997 - executive vice president/chief operating officer, Merck-Medco Managed Care, L.L.C.
    April 1997 - senior vice president, Quality Commercial Affairs, Merck Manufacturing Division (MMD)
    May 1996 - senior vice president, North American Operations, MMD
    October 1994 - vice president, North American Operations, MMD

Kenneth C. Frazier, age 46
    December 1999 - senior vice president and general counsel: responsible for legal and public affairs functions and The Merck Company Foundation (a not-for-profit charitable organization affiliated with the Company)
    January 1999 - vice president and deputy general counsel
    January 1997 - vice president, Public Affairs and assistant general counsel: responsible for public affairs, corporate legal activities and The Merck Company Foundation
    April 1994 - vice president, Public Affairs

Bernard J. Kelley, age 59
    December 1993 - president, Merck Manufacturing Division

Judy C. Lewent, age 52
    February 2001 - executive vice president and chief financial officer: responsible for financial and corporate development functions, internal auditing, corporate licensing, the Company's joint venture relationships, and Merck Capital Ventures, LLC, a wholly-owned subsidiary of the Company
    November 2000 - senior vice president and chief financial officer: responsible for financial and corporate development functions, internal auditing, corporate licensing, the Company's joint venture relationships, and Merck Capital Ventures, LLC, a wholly-owned subsidiary of the Company
    January 1997 - senior vice president and chief financial officer: responsible for financial and corporate development functions, internal auditing and the Company's joint venture relationships
    September 1994 - senior vice president and chief financial officer (since January, 1993): responsible for financial and public affairs functions, The Merck Company Foundation (a not-for-profit charitable organization affiliated with the Company) (since December, 1993), internal auditing and the Company's joint venture relationships

Adel Mahmoud, M.D., Ph.D., age 59
    May 1999 - president, Merck Vaccines
    November 1998 - executive vice president, Merck Vaccines
    Prior to November 1998, Dr. Mahmoud was the John H. Hord professor and chairman, Department of Medicine and physician-in-chief, Case Western Reserve University and University Hospitals of Cleveland (1987-1998)

Edward M. Scolnick, M.D., age 60
    December 1999 - executive vice president, Science and Technology and president, Merck Research Laboratories (MRL): responsible for worldwide research function, computer resources and corporate licensing
    September 1994 - executive vice president (since January, 1993), Science and Technology and president, MRL (since May, 1985): responsible for worldwide research function and activities of Merck Manufacturing Division (since December, 1993), computer resources (since January, 1993) and corporate licensing

Per Wold-Olsen, age 53
    January 1997 - president, Human Health-Europe, Middle East & Africa: responsible for the Company's prescription drug business in Europe, the Middle East and Africa and worldwide human health marketing
    September 1994 - president, Human Health-Europe: responsible for the Company's European prescription drug business

Wendy L. Yarno, age 46
    December 1999 - senior vice president, Human Resources
    June 1999 - vice president, Human Resources
    January 1999 - vice president, Worldwide Human Health Marketing
    November 1997 to January 1999, Ms. Yarno was vice president, Women's Health Care, Johnson & Johnson, Ortho-McNeil Pharmaceutical (manufacturer of pharmaceuticals)
    January 1995 to November 1997 - vice president, Hypertension and Heart Failure Therapeutic Business Group, U.S. Human Health

Back to Management Committee